ELEVATED neurofilament light chain (NfL) may reveal neuronal injury in people carrying the Huntington’s disease genetic expansion before the structural brain changes used to define the next disease stage become apparent.
A cross-sectional analysis found raised NfL in a substantial proportion of participants classified at the earliest stage of the Huntington’s Disease Integrated Staging System (HD-ISS). The findings suggest that fluid biomarkers could complement existing criteria and help refine participant selection for research into early interventions.
Mapping Biomarkers Across Disease Stages
Researchers analysed 78 participants in the Barcelona BCN-HD cohort, comprising 50 genetic expansion carriers and 28 controls. Findings were examined in the independent HDClarity cohort of 218 participants, including 166 expansion carriers and 52 controls.
Investigators measured cerebrospinal fluid (CSF) and plasma NfL, CSF mutant huntingtin and total tau, alongside brain imaging and clinical assessments. Genetic expansion carriers were classified across HD-ISS Stages 0–3.
Stage 0 precedes the imaging-defined striatal atrophy that marks Stage 1. Later stages reflect measurable motor or cognitive changes, followed by functional decline. The researchers explored whether fluid biomarkers identified additional biological differences within this framework.
Raised NfL at the Earliest Stage
CSF NfL increased across disease stages and distinguished Stage 0 from Stage 1, as well as premanifest from manifest disease. Plasma concentrations showed a similar pattern and strongly correlated with CSF NfL.
More than half of Stage 0 participants had NfL concentrations above the age-adjusted 95th percentile of control-derived reference values. Raised concentrations were associated with shorter model-predicted time to clinical onset, with estimates of approximately 13 years for CSF and 10 years for plasma in the relevant groups.
These figures represent predictions rather than observed time to symptom development. Higher NfL also correlated with greater genetic disease burden, striatal atrophy and poorer clinical measures.
Mutant huntingtin was detectable from Stage 0 but showed weaker associations, with very low concentrations complicating quantification. Total tau increased mainly at Stage 3, suggesting greater relevance to later neurodegeneration.
Supporting Earlier Research Stratification
The findings support investigation of NfL as an additional measure of biological disease activity. CSF testing showed stronger discrimination at the earliest stages, while blood testing could offer a more practical approach for larger studies.
However, the cross-sectional design cannot determine the sequence of biomarker changes or establish whether elevated concentrations predict future clinical transitions. Some stage-specific groups were small, and reference limits were derived separately from each cohort’s controls.
Longitudinal studies and validated disease-specific thresholds are therefore needed. These steps will help establish whether NfL can improve early trial recruitment and identify windows for interventions intended to modify Huntington’s disease before clinical symptoms emerge.
Reference
Pérez-Pérez J et al. Neurofilament light chain and mutant huntingtin across Huntington’s Disease Integrated Staging System stages in Huntington disease: a cross-sectional multimodal analysis. Mov Disord. 2026. doi:10.1002/mds.70550.
Featured image: freshidea on AdobeStock